Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short Interest

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 4,600 shares, a growth of 39.4% from the February 29th total of 3,300 shares. Based on an average trading volume of 8,700 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Anebulo Pharmaceuticals stock. Vanguard Group Inc. grew its holdings in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) by 39.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,344 shares of the company’s stock after purchasing an additional 6,312 shares during the period. Vanguard Group Inc. owned approximately 0.09% of Anebulo Pharmaceuticals worth $68,000 as of its most recent filing with the Securities and Exchange Commission. 28.40% of the stock is owned by institutional investors and hedge funds.

Anebulo Pharmaceuticals Price Performance

NASDAQ ANEB opened at $2.87 on Friday. Anebulo Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $4.05. The firm has a market capitalization of $73.57 million, a PE ratio of -6.83 and a beta of -1.02. The company’s 50 day simple moving average is $2.63 and its 200 day simple moving average is $2.55.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings results on Tuesday, February 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Sell-side analysts anticipate that Anebulo Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.